Share This Article:

Noni Seed Oil Topical Safety, Efficacy, and Potential Mechanisms of Action

Full-Text HTML Download Download as PDF (Size:226KB) PP. 74-78
DOI: 10.4236/jcdsa.2012.22017    5,992 Downloads   10,133 Views   Citations

ABSTRACT

Background: Noni fruit and leaf juices were used to treat acne in Polynesian folk medicine. However, the potential benefit of noni seed oil (NSO) for human skin health is not as well known. Objective: The topical safety of NSO was evaluated in a repeat insult patch test with 49 adult volunteers. Comedogenicity was evaluated in 23 adolescent volunteers for four weeks. Anti-inflammatory activity was determined in-vitro with COX-2 and 5-LOX enzyme inhibition assays. Results: No reactions to NSO were observed in any of the volunteers. NSO also reduced the number of open and closed comedones in the comedogenicity test. NSO inhibited COX-2 and 5-LOX enzymes in a concentration dependent manner, but with COX-2 inhibition being more pronounced than 5-LOX. Conclusion: Noni seed oil is safe for topical use and is non-comedogenic. It also has potential anti-inflammatory activity, being a dual inhibitor of COX-2 and 5-LOX enzymes. These results indicate the potential utility of NSO for skin care applications, as well as warrant further investigation of efficacy in 5-LOX and COX-2 related pathophysiological conditions.

Cite this paper

A. K. Palu, B. J. West and C. Jarakae Jensen, "Noni Seed Oil Topical Safety, Efficacy, and Potential Mechanisms of Action," Journal of Cosmetics, Dermatological Sciences and Applications, Vol. 2 No. 2, 2012, pp. 74-78. doi: 10.4236/jcdsa.2012.22017.

References

[1] M. Y. Wang, B. J. West, C. J. Jensen, D. Nowicki, C. Su, A. K. Palu and G. Anderson, “Morinda Citrifolia (Noni): A Literature Review and Recent Advances in Noni Research,” Acta Pharmacological Sinica, Vol. 23, No. 12, 2002, pp. 1127-1141.
[2] S. L. T. Palu, “A Traditional Healer from ‘Uiha, Ha’apai, Tonga, South Pacific,” Personal Communication, Orem, 2004.
[3] A. P. Benthall, “The Trees of Calcutta and Its Neighborhood,” Spink, Calcutta, 1984.
[4] V. A. Palepale, “A Traditional Healer from Ha’alalo, Tonga, South Pacific,” Personal Communication, Lehi, 2005.
[5] J. J. Wadsworth and S. P. Story, “Morinda citrifolia Oil,” US Patent No. 6417157, 2002.
[6] S. C. Nelson, “Hawaiian Noni Seed Processing and Germination,” 2005. http://www.ctahr.hawaii.edu/noni/downloads/noniseeds.pdf
[7] A. M. Kligman, “The Identification of Contact Allergens by Human Assay. III. The Maximization Test: A Procedure for Screening and Rating Contact Sensitizers,” TheJournal of Investigative Dermatology, Vol. 47, No.5, 1966, pp. 393-409.
[8] R. L. Rietschel and J. F. Fowler, “Fisher’s Contact Dermatitis,” 4th Edition, Williams & Wilkins, Baltimore, 1995.
[9] O. H. Mills and A. M. Kligman, “The Follicular Biopsy,” Dermatologica, Vol. 167, No. 2, 1983, pp. 57-63.
[10] T. D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J. A. Mitchell and J. R. Vane, “Nonsteroid Drug Selectivities for Cyclo-Oxygenase-1 rather than Cyclo-Oxygenase-2 Are Associated with Human Gastrointestinal Toxicity: A Full in Vitro Analysis,” Proceedings of the National Academy of Sciences of the USA, Vol. 96 No. 13, 1999, pp. 7563-7568. doi:10.1073/pnas.96.13.7563
[11] D. Riendeau, S. Charleson, W. Cromlish, J. A. Mancini, E. Wong and J. Guay, “Comparison of the Cyclooxygenase-1 Inhibitory Properties of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Selective COX-2 Inhibitors, Using Sensitive Microsomal and Platelet Assays,” Canadian Journal of Physiology and Pharmacology, Vol. 75, No. 9, 1997, pp. 1088-1095. doi:10.1139/y97-130
[12] G. W. Carter, P. R. Young, D. H. Albert, J. Bouska, R. Dyer, R. L. Bell, J. B. Summers and D. W. Brooks, “5-Lipoxygenase Inhibitory Activity of Zileuton,” The Journal of Pharmacology and Experimental Therapeutics, Vol. 256, No. 3, 1991, pp. 929-937.
[13] H. Safayhi, S. E. Boden, S. Schweizer and H. P. Ammon, “Concentration-Dependent Potentiating and Inhibitory Effects of Boswellia Extracts on 5-Lipoxygenase Product Formation in Stimulated PMNL,” Planta Medica, Vol. 66, No. 2, 2000, pp. 110-113. doi:10.1055/s-2000-11136
[14] B. J. West, C. J. Jensen and J. Westendorf, “A New Vegetable Oil from Noni (Morinda citrifolia) Seeds,” International Journal of Food Science and Technology, Vol. 43, No. 11, 2008, pp. 1988-1992. doi:10.1111/j.1365-2621.2008.01802.x
[15] P. Rubin and K. W. Mollison, “Pharmacotherapy of Diseases Mediated by 5-Lipoxygenase Pathway Eicosanoids,” Prostaglandins & Other Lipid Mediators, Vol. 83, No. 3, 2007, pp. 188-197. doi:10.1016/j.prostaglandins.2007.01.005
[16] I. Kurokawa, F. W. Danby, Q. Ju, X. Wang, L. F. Xiang, L. Xia, W. Chen, I. Nagy, M. Picardo, D. H. Suh, R. Ganceviciene, S. Schagen, F. Tsatsou and C. C. Zouboulis, “New Developments in Our Understanding of Acne Pathogenesis and Treatment,” Experimental Dermatology, Vol. 18, No. 10, 2009, pp. 821-832. doi:10.1111/j.1600-0625.2009.00890.x
[17] J. J. F. Belch and A. Hill, “Evening Primrose Oil and Borage Oil in Rheumatologic Conditions,” American Journal of Clinical Nutrition, Vol. 71, No. 1, 2000, pp. 352-356.
[18] C. Letawe, M. Boone and G. E. Pierard, “Digital Image Analysis of the Effects of Topically Applied Linoleic Acid on Acne Micro-Comedones,” Clinical and Experimental Dermatology, Vol. 23, No. 2, 1998, pp. 56-58. doi:10.1046/j.1365-2230.1998.00315.x
[19] A. Klegeris and P. L. McGreer, “Cyclooxygenase and 5-Lipoxygenase Inhibitors Protect Against Mononuclear Phagocyte Neurotoxicity,” Neurobiology of Aging, Vol. 23, No. 5, 2002, pp. 787-794. doi:10.1016/S0197-4580(02)00021-0
[20] J. Pommery, N. Pommery and J. P. Henichart, “Modification of Eicosanoid Profile in Human Blood Treated by Dual COX/LOX Inhibitors,” Prostaglandins, Leukotrienes, and Essential Fatty Acids, Vol. 73, No. 6, 2005, pp. 411-417. doi:10.1016/j.plefa.2005.08.009
[21] L. Goossens, N. Pommery and J. P. Henichart, “COX2/5-LOX Dual Acting Anti-Inflammatory Drugs in Cancer Chemotherapy,” Current Topics in Medicinal Chemistry, Vol. 7, No. 3, 2007, pp. 283-296. doi:10.2174/156802607779941369
[22] C. X. Su, “A New Selective COX-2 Inhibitor: Morinda citrifolia (Noni). Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases,” 7th Annual Conference, Nashville, 14-17 October 2001.
[23] A. K. Palu, C. Su, B. N. Zhou and J. Jensen, “Morinda citrifolia L.: A Dual Inhibitor of COX-2 and 5-LOX Enzymes,” 5th International Conference and Exhibition on Nutraceuticals and Functional Foods, San Francisco, 7-10 November 2004.
[24] A. Valentino, M. Fimiani, R. Baiocchi, R. Bilenchi, R. Perotti, A. Castelli, M. L. Mancianti and M. Raffaelli, “Cosmetic Acne and a Test of Comedogenicity,” Bollettino Della Società Italiana di Biologia Sperimentale, Vol. 60, No. 10, 1984, pp. 1845-1848.
[25] C. R. Srinivas, A. Padhee, C. Balanchandran, S. D. Shenoy, S. Acharya and K. Ramnaraya, “Comedones Induced by Coconut Oil in a Borderline Tuberculoid Lesion,” International Journal of Leprosy and Other Mycobacterial Diseases, Vol. 56, No. 3, 1988, pp. 471-472.
[26] J. A. Menendez, L. R. Vellon, R. Colomer and R. Lupu, “Oleic Acid, the Main Monounsaturated Fatty Acid of Olive Oil, Suppresses Her-2/neu (erbB-2) Expression and Synergistically Enhances the Growth Inhibitory Effects of Trastuzumab (HerceptinTM) in Breast Cancer Cells with Her-2/neu Oncogene Amplification,” Annals of Oncology, Vol. 16, No. 3, 2005, pp. 359-371. doi:10.1093/annonc/mdi090
[27] V. M. Flood, K. L. Webb, E. Rochtchina, B. Kelly and P. Mitchell, “Fatty Acid Intakes and Food Sources in a Population of Older Australians,” Asia Pacific Journal of Clinical Nutrition, Vol. 16, No. 2, 2007, pp. 322-330.
[28] G. Irmisch, D. Schlafke, W. Gierow, S. Herpertza and J. Richter, “Fatty Acids and Sleep in Depressed Inpatients,” Prostaglandins, Leukotrienes, and Essential Fatty Acids, Vol. 76, No. 1, 2007, pp. 1-7. doi:10.1016/j.plefa.2006.09.001
[29] C. D. Daulatabad, G. M. Mulla and A. M. Mirajkar, “Ricinoleic Acid in Morinda citrifolia Seed Oil,” Journal of Oil and Technologists Association, Vol. 21, No. 2, 1989, pp. 26-27.
[30] A. Kogan and N. Garti, “Microemulsions as Transdermal Drug Delivery Vehicles,” Advanced Colloid and Interface Science, Vol. 123-126, 2006, pp. 369-385. doi:10.1016/j.cis.2006.05.014
[31] L. C. Zhang, J. H. Hu and L. Li, “In Vivo and in Vitro Evaluation of Essential Oils from Ligusticum chuanxiong HORT on the Transdermal Delivery of Flurbiprofen in Rabbits,” Biological & Pharmaceutical Bulletin, Vol. 29, No. 6, 2006, pp. 1217-1222. doi:10.1248/bpb.29.1217
[32] R. Jantharaprapap and R. Stagni, “Effects of Penetration Enhancers on in Vitro Permeability of Meloxicam Gels,” International Journal of Pharmaceutics, Vol. 343, No. 1-2, 2007, pp. 26-33. doi:10.1016/j.ijpharm.2007.04.011
[33] G. Martin-Ezquerra, M. Sanchez-Regana and P. UmbertMillet, “Optimization of Narrow-Band UVB with a 5% Oleic Acid Cream in the Treatment of Psoriasis,” Journal of Drugs in Dermatology, Vol. 6, No. 3, 2007, pp. 290-292.

  
comments powered by Disqus

Copyright © 2017 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.